Post-traumatic stress disorder, commonly referred to as PTSD, is a mental health condition that is usually triggered by a petrifying event that one witnesses or experiences. The most common symptoms of the disorder include severe anxiety, upsetting dreams or nightmares, and flashbacks. Other symptoms include severe physical reactions or emotional distress in response to a situation that makes an individual recall the traumatic event or recurrent distressing memories of the event.
Estimates show that post-traumatic stress disorder affects about seven million individuals in the United States. This disorder has been linked to various conditions, including anxiety and depression, as well as the heightened risk of heart attacks. This is why researchers are focused on developing new and effective therapies to manage and treat it.
A recently published study looked into the effectiveness of cognitive-behavioral conjoint therapy (“CBCT”) combined with the administration of MDMA in some sessions as a treatment option. The study recruited six couples, with researchers revealing that in every pair, one partner had been diagnosed with post-traumatic stress disorder. The study’s 12 participants were all heterosexual couples and were Caucasian.
Conjoint therapy has demonstrated its effectiveness in the treatment of this particular disorder, as its treatment target centers on the relationship between the participants. The researchers used MDMA for their study as it possesses empathogenic qualities and is known to enhance feelings of togetherness and emotional connectedness. The psychedelic’s administration was timed to concur with associated aspects of conjoint therapy’s interventions, such as communication skills development.
According to partner- and self-rated symptoms as well as assessments conducted by clinicians, the researchers stated that they observed substantial and sustained improvements in post-traumatic stress disorder. The researchers also noted that beliefs associated with trauma, emotion regulation and overall depression improved tremendously.
In their report, the researchers note that the study’s generalizability and power was low, adding that no control groups were used in the study. The lack of control groups makes it harder to recognize whether MDMA-assisted cognitive behavioral conjoint therapy under- or outperformed traditional conjoint therapy.
Despite this, The study noted that facilitating this therapy form with MDMA doesn’t prevent its effectiveness. However, more research is needed to better understand its influence and how it interacts with therapy as well as its outcomes.
The study was conducted by Michael C. Mithoefe, Anne C. Wagnera, Rick Doblin, Ann T. Mithoefer, Amy Emerson, Rachel E. Liebman, Betta Yazar-Klosinski, Lisa Jerome, Allison A. Feduccia and Candice M. Monson.
The work done by this group of researchers can be tied to the work of companies such as Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), which are looking to develop and commercialize a variety of psychedelic-based medicines for mental health diseases.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.